Hepatocellular CarcinomaPhase 2NCT05257590
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
A Phase 2 study testing Nivolumab Injection [Opdivo] and CVM-1118 in people with Hepatocellular Carcinoma and Advanced Cancer, run by TaiRx, Inc. at 5 sites in Taiwan.
Trial summary
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human has been evaluated from the phase 1 study. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hepatocellular Carcinoma, Advanced Cancer
- What is being tested?
- Nivolumab Injection [Opdivo] and CVM-1118
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 95 participants
- Where
- 5 sitesTaiwan
- Study dates
- 23 May 2022to 31 Dec 2026
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18+ (20+ for subjects in Taiwan)
- Diagnosis of hepatocellular carcinoma
- Pathologically or cytologically-confirmed or clinically diagnosed in accordance with American Association for the Study of Liver Diseases (AASLD) criteria (i.e., radiologic imaging with cross-sectional multiphasic contrast CT or MRI showing a ≥ 1 cm liver lesion)
- Subjects with advanced-stage, unresectable hepatocellular carcinoma that is not appropriate for potentially curable therapy who have progressed from, been intolerant of prior systemic anti-cancer therapies (e.g., sorafenib, lenvatinib, atezolizumab in combination with bevacizumab).
- Barcelona Clinic Liver Cancer (BCLC) stage B not appropriate for or with disease progression after local regional therapy, or BCLC stage C
- Child-Pugh liver function class A
Show all 22Show fewer
- Measurable disease (per mRECIST)
- ECOG performance status of 0 to 1
- Adequate laboratory parameters including:
- AST and ALT ≤ 3.0 x ULN (≤ 5.0 x ULN if due to liver involvement)
- Total serum bilirubin ≤ 2.0 x ULN (≤ 3.0 x ULN for subjects with documented Gilbert's syndrome)
- ANC ≥1500/µL
- Platelets ≥ 90,000/µL
- HGB ≥ 9.0 g/dL
- Serum creatinine clearance of ≥ 50 mL/min based on Cockcroft-Gault formula
- Serum albumin ≥ 2.8 gm/dL
- INR ≤ 2.3
- PT/aPTT ≤ 1.2 x ULN
- QTcF ≤ 480 msec
- Subjects are eligible to enroll if they have HBV-, or HCV-HCC, defined as follows:
- Chronic HBV infection as evidenced by detectable HBV DNA or HBsAg. Subjects with chronic HBV infection must be on antiviral therapy and have HBV DNA <500 IU/mL. If not on an antiviral therapy at screening, then subjects must be willing to start the antiviral therapy at the time of consent.
- Active or resolved HCV infection as evidenced by detectable HCV RNA or antibody.
Who cannot join
- HCC with portal vein invasion at the main portal branch (Vp4)
- Known history of esophageal varices or gastrointestinal bleeding within the past 3 months
- Prior immunotherapy for hepatoma
- ≤ 7 days from prior limited field palliative irradiation therapy and C1D1
- ≤ 28 days from prior irradiation therapy and C1D1
- ≤ 14 days (or 5 half-lives) from prior systemic anticancer therapy and C1D1
Show all 15Show fewer
- ≤ 28 days from local regional therapy (e.g., trans-arterial embolization, radiofrequency ablation) and C1D1
- Presence of other active cancer(s) likely to require treatment in the next two (2) years or likely to impact the assessment of any study endpoints
- Active bacterial or fungal infection(s) requiring systemic therapy within 7 days prior to C1D1
- Known CNS metastases
- Known history of HIV infection
- Females who are currently pregnant or breast-feeding
- Known gastrointestinal disease that may significantly alter the absorption of oral medications
- Psychiatric illness or social situation that would interfere with compliance with study requirements
- History of clinically significant cardiovascular abnormalities
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
Taiwan5 sites, 5 recruiting
- Recruiting
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City
Sheng-Nan Lu, MD/Ph.D
- Recruiting
Keelung Chang Gung Memorial Hospital
Keelung
Kun-Yun Yeh, MD/Ph.D
- Recruiting
National Cheng Kung University Hospital
Tainan
Yan-Shen Shan, MD/PhD
- Recruiting
National Taiwan University Hospital
Taipei, 100
Pei-Jer Chen, MD/PhD
- Recruiting
Taipei Veterans General Hospital
Taipei, 112
Yi-Hsiang Huang, MD/PhD
About this study
Official title: A Phase 2, Open-Label Study of CVM-1118 in Combination With Nivolumab in Subjects With Unresectable Advanced Hepatocellular Carcinoma
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human has been evaluated from the phase 1 study. The objective of the phase 2 study is to further investigate the efficacy of CVM-1118 with nivolumab for subjects with unresectable advanced hepatoma.
Read the detailed description
Nivolumab, a human IgG4 kappa monoclonal antibody acts as a checkpoint inhibitor, blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2 ) and therefore preventing the activation of T cells from attacking the cancer. Nivolumab is currently approved for several cancer types.
To meet the medical need, TaiRx, Inc. develops a new small molecule drug, CVM-1118 can promote apoptosis and delay proliferation. Moreover, CVM-1118 targets the formation of vasculogenic mimicry (VM). VM has been associated with tumor metastasis and poor clinical outcomes. VM is reported to be particularly active in tumor under hypoxia state when patients are treated with the potent vascular endothelial growth factor (VEGF) inhibitor like sorafenib or bevacizumab. Hence, the ability of inhibiting the VM network makes CVM-1118 a potential good combination drug with Nivolumab in advanced diseases such as hepatoma where Nivolumab alone has shown activity.
The safety profile of CVM-1118 dosing has been established in the phase 1 study. The analysis of metabolism pathways further showed that the potential drug-drug interactions of CVM-1118 and Nivolumab are very low.
Based on the mechanism of actions and the safety analysis of nivolumab and CVM-1118, the design of phase 2 trial with the combination therapy might have great potential for the patients with unresectable advanced HCC.
- Conditions
- Hepatocellular Carcinoma, Advanced Cancer
- Being tested
- Nivolumab Injection [Opdivo], CVM-1118
- Keywords
- Oncology, Hepatocellular Carcinoma (HCC), Nivolumab, Hepatoma
- Medical subject headings
- Carcinoma, Hepatocellular, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nivolumab Injection [Opdivo]Drug
Also called Nivolumab
Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.
CVM-1118Drug
Also called TRX-818
CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.
| Study group | Role | What they receive |
|---|---|---|
| Nivolumab + CVM-1118 | Experimental | 1 Cycle = 28 days
Nivolumab, 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting from Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.
CVM-1118, 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects. Escalation of the starting dose will be dependent on the absence of Dose Limiting Toxicity in at least 7 of the initial 10 subjects treated at 200 mg, PO, BID.
Individual subjects receiving a starting dose of 200 mg, PO, BID and who tolerate the initial 2 cycles with no more than Grade 2 related toxicity, will have the option of increasing their dose of CVM-1118 to 300 mg, PO, BID (600 mg total daily dose) starting with cycle 3
Tolerable dose of Nivolumab and CVM-1118 will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal. Receives: Drug: Nivolumab Injection [Opdivo]; Drug: CVM-1118 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Objective Response Rate (ORR)_mRECIST
Assessment by modified RECIST criteria
Measured: 24 weeks after the last subject starts CVM-1118
Secondary outcomes (21)
Objective Response Rate (ORR)_RECIST v1.1
Assessment by RECIST v1.1 criteria
Measured: 24 weeks after the last subject starts CVM-1118
Duration of response (DoR)
Duration of response (DoR) is defined as time from the first documentation of response to the time of progression
Measured: 24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose
Progression free survival (PFS)
Progression free survival (PFS) is defined as time from the first dose of study drug to the time of progression or death
Measured: 24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose
Overall survival (OS)
Overall survival (OS) is defined as time from first dose of study drug to death
Measured: 24 weeks after the last subject starts CVM-1118 and up to 1 year after the last-dose
Time to progression (TTP)
Time to progression (TTP) is defined as the time from the first dose of study drug to the time of progression
Measured: 24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose
Disease control rate (DCR)
Disease control rate (DCR) is defined as the sum of complete response (CR), partial response (PR), and stable disease rate (SD)
Measured: 24 weeks after the last subject starts CVM-1118 and up to 1 year after the last-dose
Rate of Adverse event (AE) and Serious Adverse Event (SAE)
Rate of Adverse event (AE) and Serious Adverse Event (SAE) are assessed using Common Terminology Criteria for Adverse Events v.5 (CTCAE) criteria
Measured: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment by CTCAE v5.
Number of Participants With Abnormal Vital Sign
Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.
Measured: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ blood pressure (both systolic and diastolic blood pressure) by CTCAE v5
Both systolic and diastolic blood pressure will be measured. Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.
Measured: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ Heart rate by CTCAE v5
Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.
Measured: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ respiratory rate by CTCAE v5
Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.
Measured: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Number of Participants With Abnormal baseline and out-of range Hematology Count by CTCAE v5
Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.
Measured: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range coagulation test by CTCAE v5
Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.
Measured: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range urinalysis test by CTCAE v5
Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.
Measured: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Number of patients with abnormalities in electrocardiography (ECG) reporting for PR, QRS, QT, and QTcF intervals
Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.
Measured: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Maximum Plasma Concentration [Cmax] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing
Maximum Plasma Concentration [Cmax] of CVM-1118 and its metabolite CVM-1125 will be measured to see maximum exposure after CVM-1118 dosing
Measured: During Cycle 1 and Cycle 2 (each cycle is 28 days)
Area Under the Curve [AUC] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing
Area Under the Curve [AUC] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing
Measured: During Cycle 1 and Cycle 2 (each cycle is 28 days)
Pharmacodynamics analysis for the relationship of Cmax and ORR
Relationship between Cmax and ORR will be evaluated
Measured: During Cycle 1 and Cycle 2 (each cycle is 28 days)
Pharmacodynamics analysis for the relationship of AUC and ORR
Relationship between AUC and ORR will be evaluated
Measured: During Cycle 1 and Cycle 2 (each cycle is 28 days)
Pharmacodynamics analysis for the relationship of Cmax and AE
Relationship between Cmax and AE will be evaluated
Measured: During Cycle 1 and Cycle 2 (each cycle is 28 days)
Pharmacodynamics analysis for the relationship of AUC and AE
Relationship between AUC and AE will be evaluated
Measured: During Cycle 1 and Cycle 2 (each cycle is 28 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2022
- Study start23 May 2022
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatocellular CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 95 participants (estimated)
Sponsor and investigators
- Lead sponsor
- TaiRx, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pei-Jer Chen, MD/PhD, Principal investigator, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05257590
- Sponsor's protocol ID
- CVM-008
- Status last verified
- Apr 2026
- First submitted
- 8 Feb 2022
- Last updated
- 13 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Open-Label Study of CVM-1118 in Combination With Nivolumab in Subjects With Unresectable Advanced Hepatocellular Carcinoma
- ClinicalTrials.gov ID
- NCT05257590
- Acronym / sponsor ID
- CVM-008
- Conditions
- Hepatocellular Carcinoma, Advanced Cancer
- Keywords
- Oncology, Hepatocellular Carcinoma (HCC), Nivolumab, Hepatoma
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 95 participants (estimated)
- Lead sponsor
- TaiRx, Inc.Industry (pharma, biotech, devices)
- Study start
- 23 May 2022 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 25 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human has been evaluated from the phase 1 study. The objective of the phase 2 study is to further investigate the efficacy of CVM-1118 with nivolumab for subjects with unresectable advanced hepatoma.
Detailed description
Nivolumab, a human IgG4 kappa monoclonal antibody acts as a checkpoint inhibitor, blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2 ) and therefore preventing the activation of T cells from attacking the cancer. Nivolumab is currently approved for several cancer types.
To meet the medical need, TaiRx, Inc. develops a new small molecule drug, CVM-1118 can promote apoptosis and delay proliferation. Moreover, CVM-1118 targets the formation of vasculogenic mimicry (VM). VM has been associated with tumor metastasis and poor clinical outcomes. VM is reported to be particularly active in tumor under hypoxia state when patients are treated with the potent vascular endothelial growth factor (VEGF) inhibitor like sorafenib or bevacizumab. Hence, the ability of inhibiting the VM network makes CVM-1118 a potential good combination drug with Nivolumab in advanced diseases such as hepatoma where Nivolumab alone has shown activity.
The safety profile of CVM-1118 dosing has been established in the phase 1 study. The analysis of metabolism pathways further showed that the potential drug-drug interactions of CVM-1118 and Nivolumab are very low.
Based on the mechanism of actions and the safety analysis of nivolumab and CVM-1118, the design of phase 2 trial with the combination therapy might have great potential for the patients with unresectable advanced HCC.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Nivolumab + CVM-1118 | Experimental | Drug: Nivolumab Injection [Opdivo], Drug: CVM-11181 Cycle = 28 days Nivolumab, 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting from Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability. CVM-1118, 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects. Escalation of the starting dose will be dependent on the absence of Dose Limiting Toxicity in at least 7 of the initial 10 subjects treated at 200 mg, PO, BID. Individual subjects receiving a starting dose of 200 mg, PO, BID and who tolerate the initial 2 cycles with no more than Grade 2 related toxicity, will have the option of increasing their dose of CVM-1118 to 300 mg, PO, BID (600 mg total daily dose) starting with cycle 3 Tolerable dose of Nivolumab and CVM-1118 will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (22 listed)
- Age 18+ (20+ for subjects in Taiwan)
- Diagnosis of hepatocellular carcinoma
- Subjects with advanced-stage, unresectable hepatocellular carcinoma that is not appropriate for potentially curable therapy who have progressed from, been intolerant of prior systemic anti-cancer therapies (e.g., sorafenib, lenvatinib, atezolizumab in combination with bevacizumab).
- Barcelona Clinic Liver Cancer (BCLC) stage B not appropriate for or with disease progression after local regional therapy, or BCLC stage C
- Child-Pugh liver function class A
Key exclusion criteria (15 listed)
- HCC with portal vein invasion at the main portal branch (Vp4)
- Known history of esophageal varices or gastrointestinal bleeding within the past 3 months
- Prior immunotherapy for hepatoma
- ≤ 7 days from prior limited field palliative irradiation therapy and C1D1
- ≤ 28 days from prior irradiation therapy and C1D1
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nivolumab Injection [Opdivo]Also: NivolumabNivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability. | Drug | Nivolumab + CVM-1118 |
| CVM-1118Also: TRX-818CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects. | Drug | Nivolumab + CVM-1118 |
Primary outcome
Objective Response Rate (ORR)_mRECIST
Time frame: 24 weeks after the last subject starts CVM-1118
Assessment by modified RECIST criteria
21 secondary outcomes
Objective Response Rate (ORR)_RECIST v1.1
Time frame: 24 weeks after the last subject starts CVM-1118
Duration of response (DoR)
Time frame: 24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose
Progression free survival (PFS)
Time frame: 24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose
Overall survival (OS)
Time frame: 24 weeks after the last subject starts CVM-1118 and up to 1 year after the last-dose
Time to progression (TTP)
Time frame: 24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose
Disease control rate (DCR)
Time frame: 24 weeks after the last subject starts CVM-1118 and up to 1 year after the last-dose
Rate of Adverse event (AE) and Serious Adverse Event (SAE)
Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment by CTCAE v5.
Number of Participants With Abnormal Vital Sign
Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ blood pressure (both systolic and diastolic blood pressure) by CTCAE v5
Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ Heart rate by CTCAE v5
Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ respiratory rate by CTCAE v5
Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Number of Participants With Abnormal baseline and out-of range Hematology Count by CTCAE v5
Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range coagulation test by CTCAE v5
Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range urinalysis test by CTCAE v5
Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Number of patients with abnormalities in electrocardiography (ECG) reporting for PR, QRS, QT, and QTcF intervals
Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Maximum Plasma Concentration [Cmax] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing
Time frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)
Area Under the Curve [AUC] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing
Time frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)
Pharmacodynamics analysis for the relationship of Cmax and ORR
Time frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)
Pharmacodynamics analysis for the relationship of AUC and ORR
Time frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)
Pharmacodynamics analysis for the relationship of Cmax and AE
Time frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)
Pharmacodynamics analysis for the relationship of AUC and AE
Time frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2026.
Related trials for Hepatocellular Carcinoma
RecruitingObservational study
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Liver Neoplasms, Primary Liver Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingObservational study
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Lung Cancer, Hepatocellular Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Pei-Jer Chen, MD/PhD principal investigator
National Taiwan University Hospital
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Nivolumab Injection [Opdivo] and CVM-1118 in people with Hepatocellular Carcinoma and Advanced Cancer, run by TaiRx, Inc. at 5 sites in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 22 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yen-Ling Chen, PhD (886-2-2653-5007 ext. 113, yenlingchen@trx.com.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Objective Response Rate (ORR)_mRECIST (time frame: 24 weeks after the last subject starts CVM-1118). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2026; AzTrials last refreshed its copy on 6 Nov 2026.